Vaxart

Valuation Analysis

About the Company

Vaxart en bref

Vaxart (VXRT) is currently trading at 0,48 € with a market capitalization of 116 M €. The trailing P/E ratio stands at 3.44x. The 52-week range spans from 0,23 € to 0,73 €; the current price is 34.5% below the yearly high. Year-over-year revenue growth stands at +87.9%. The net profit margin stands at 14.51%.

💰 Dividende

Vaxart currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

2 analystes évaluent Vaxart (VXRT) au consensus : None. L'objectif de cours moyen est de 2,62 €, soit un potentiel de +444.46% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 1,75 € à 3,49 €.

Vaxart : la thèse d'investissement en détail

Vaxart (VXRT) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 87.9% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Return on equity of 53.1% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Valorisation en contexte

The EV/EBITDA multiple of 1.91x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The analyst consensus price target implies 444.46% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to market-like volatility, elevated short interest (9.4%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Vaxart?

Compare top-rated brokers — low fees, trusted providers, fully regulated.